Tianjin Lisheng Pharmaceutical Company Ltd. (SZ: 002393) announced its financial results for the fiscal year ended December 31, 2025. The company achieved operating revenue of 1.392 billion yuan, representing a year-on-year increase of 4.18%. Net profit attributable to shareholders of the listed company was 416 million yuan, a significant increase of 125.59% compared to the previous year. Basic earnings per share for the period were 1.62 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments